Outcomes and Safety of Outpatient Parenteral Antimicrobial Therapy in Select Children with Cystic Fibrosis

Pediatric Allergy, Immunology, and Pulmonology
Gulnur ComAriel Berlinski

Abstract

Background: Pulmonary exacerbations (PExs) are common in individuals with cystic fibrosis (CF). Data regarding outcomes of outpatient parenteral antimicrobial therapy (OPAT) in children are sparse. Methods: Retrospective data of PEx episodes treated in the hospital versus OPAT collected. Children ≤18 years were included. Outcome measures included FEV1, FVC, FEF25-75%P, time to the next PEx, and weight gain. Results: Eighty-three subjects with 290 PEx events were eligible. The hospital group had 242 and the OPAT group had 48 PEx events. The median age was 13.1 years for the OPAT and 13.4 years for the hospital group. Medicaid coverage was higher in the hospital group (82.2%) versus OPAT group (48.9%, P < 0.0001). The hospital group had lower FEV1%P on admission [72%P (interquartile range [IQR] = 59.7 and 84) versus 80%P (IQR = 70.7 and 89); P = 0.001] and at the end of treatment [86%P (IQR = 72 and 96.7) versus 92%P (IQR = 82 and 101); P = 0.003] in comparison with OPAT group. FEV1%P improved more in the hospital group, [12%P (IQR = 4 and 20)] versus in the OPAT group [8%P (IQR = 2 and 22.5); (P = 0.41)] but did not quite reach a statistically significant level. The hospital intravenous (IV) group gained more weight (P < 0....Continue Reading

References

Apr 1, 1992·Acta Paediatrica·B StrandvikB Widén
May 1, 1988·Archives of Disease in Childhood·J GilbertJ M Littlewood
Jul 1, 1997·Pediatric Pulmonology·D G Bosworth, D W Nielson
May 24, 2001·American Journal of Respiratory and Critical Care Medicine·M S SchechterS C Fitzsimmons
Jul 3, 2003·The Journal of Pediatrics·Michael W KonstanUNKNOWN Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
Oct 26, 2005·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·J ThorntonA K Webb
Jan 5, 2006·Journal of Clinical Nursing·Glenda EsmondAnne Marie McCormack
Jul 18, 2009·The Journal of Pediatrics·Michael S SchechterUNKNOWN North American Scientific Advisory Group for ESCF
May 14, 2010·American Journal of Respiratory and Critical Care Medicine·Don B SandersChristopher H Goss
Jun 29, 2010·American Journal of Respiratory and Critical Care Medicine·J Michael CollacoPeter J Mogayzel
Dec 2, 2011·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Moran LavieOri Efrati
Apr 3, 2012·Pediatric Pulmonology·Gregory S Sawicki, Harm Tiddens
Nov 16, 2017·Annals of the American Thoracic Society·Michael S SchechterUNKNOWN Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
Dec 15, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anne H NorrisCraig A Umscheid

❮ Previous
Next ❯

Software Mentioned

R
OPAT

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.